Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Specialized psychosocial interventions—including meaning-centered psychotherapy—can greatly improve a cancer patient's quality of life and reduce suffering.
Cancer patients on active treatment are 35% less likely to develop COVID-19 than patients not receiving treatment, though those who did test positive for SARS-CoV-2 experienced higher death rates.
Restoring an enzyme that maintains the way chromosomes are packed inside cells may lead to new therapies for some blood cancers, according to a new study by Columbia researchers.
The HPV vaccine has great potential to reduce the rate of cervical cancer in Africa, where Columbia researchers are trying to increase vaccination rates with texts.
Cancer patients are especially vulnerable to COVID and would benefit from the protection the vaccine offers, says Gary Schwartz, MD, deputy director of the Herbert Irving Comprehensive Cancer Center.
A new study has found that up to 20% of aggressive brain cancers are fueled by overactive mitochondria and new drugs in development may be able to starve the cancers.
A new study conducted at Columbia and other centers found that 80% of patients with a type of slow-growing lymphoma achieved a complete remission with a single infusion of CAR T-cell immunotherapy.
For multiple myeloma patients with RAS mutations, inhibiting an enzyme involved in cell proliferation may help patients resistant to current therapies, a new Columbia study has found.